About Nuevocor
Nuevocor is a company based in Singapore (Singapore) founded in 2021 by Yann Chong Tan.. Nuevocor has raised $80.6 million across 3 funding rounds from investors including Kurma Partners, Angelini Ventures and EDBI. Nuevocor offers products and services including NVC-001. Nuevocor operates in a competitive market with competitors including Senti Biosciences, AskBio, Tenaya Therapeutics, Bluebird Bio and Inotrem, among others.
- Headquarter Singapore, Singapore
- Founders Yann Chong Tan
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nuevocor Pte. Ltd.
-
Annual Revenue
-
Net Profit
$-6.02 M (USD)-79as on Mar 31, 2023
-
EBITDA
$-6.02 M (USD)-79as on Mar 31, 2023
-
Total Equity Funding
$80.6 M (USD)
in 3 rounds
-
Latest Funding Round
$45 M (USD), Series B
May 06, 2025
-
Investors
Kurma Partners
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nuevocor
Nuevocor offers a comprehensive portfolio of products and services, including NVC-001. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Genetic medicine targeting lamin-related dilated cardiomyopathy for heart treatment.
Unlock access to complete
Unlock access to complete
Funding Insights of Nuevocor
Nuevocor has successfully raised a total of $80.6M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $45 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $45.0M
-
First Round
First Round
(18 Jun 2021)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2025 | Amount | Series B - Nuevocor | Valuation | Kurma Partners , Angelini Ventures | |
| Nov, 2022 | Amount | Series B - Nuevocor | Valuation |
investors |
|
| Jun, 2021 | Amount | Series A - Nuevocor | Valuation | EVX Ventures , Boehringer Ingelheim Venture Fund |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nuevocor
Nuevocor has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Kurma Partners, Angelini Ventures and EDBI. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are funded through venture capital in life sciences.
|
Founded Year | Domain | Location | |
|
Angelini Ventures is focused on investing in BioTech and Digital Health.
|
Founded Year | Domain | Location | |
|
Government-backed investments are directed toward healthcare, fintech, and various sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nuevocor
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nuevocor
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nuevocor Comparisons
Competitors of Nuevocor
Nuevocor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, AskBio, Tenaya Therapeutics, Bluebird Bio and Inotrem, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for severe genetic and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nuevocor
Frequently Asked Questions about Nuevocor
When was Nuevocor founded?
Nuevocor was founded in 2021.
Where is Nuevocor located?
Nuevocor is headquartered in Singapore, Singapore.
Is Nuevocor a funded company?
Nuevocor is a funded company, having raised a total of $80.6M across 3 funding rounds to date. The company's 1st funding round was a Series A of $24M, raised on Jun 18, 2021.
What does Nuevocor do?
Founded in 2021 and based in Singapore, Nuevocor operates in the biotechnology sector with a focus on gene therapy development for cardiovascular conditions. Recombinant adeno-associated virus-based therapies are being advanced, including a lead candidate for dilated cardiomyopathy linked to Lamin AC (LMNA) gene mutations. Operations center on clinical and preclinical research to address genetic causes of heart disease in patients.
Who are the top competitors of Nuevocor?
Nuevocor's top competitors include Senti Biosciences, Juvenescence and AskBio.
What products or services does Nuevocor offer?
Nuevocor offers NVC-001.
Who are Nuevocor's investors?
Nuevocor has 9 investors. Key investors include Kurma Partners, Angelini Ventures, EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund.